Walleye Capital’s Altimmune ALT Stock Holding History

Walleye Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.8K	Buy	8,499 +8,497	+424,850%	+$25.4K	﹤0.01%	4343
2026 Q1	$6	Sell	2 -65,663	-100%	-$279K	﹤0.01%	4313
2025 Q4	$237K	Buy	65,665 +50,147	+323%	+$219K	﹤0.01%	3449
2025 Q3	$58.5K	Buy	+15,518	New	+$59.9K	﹤0.01%	3953
2025 Q1	–	Sell	-22,224	Closed	-$160K	–	4193
2024 Q4	$160K	Buy	+22,224	New	+$170K	﹤0.01%	3893
2024 Q3	–	Sell	-23,000	Closed	-$153K	–	5220
2024 Q2	$153K	Sell	23,000 -11,813	-34%	-$87.2K	﹤0.01%	4475
2024 Q1	$354K	Buy	34,813 +11,206	+47%	+$114K	﹤0.01%	3508
2023 Q4	$266K	Buy	+23,607	New	+$98.6K	﹤0.01%	3469
2023 Q3	–	Sell	-419,783	Closed	-$1.48M	–	4830
2023 Q2	$1.48M	Buy	419,783 +372,544	+789%	+$1.67M	0.01%	1541
2023 Q1	$199K	Buy	+47,239	New	+$561K	﹤0.01%	2475
2022 Q3	–	Sell	-134,993	Closed	-$1.99M	–	3201
2022 Q2	$1.58M	Sell	134,993 -76,760	-36%	-$473K	0.04%	443
2022 Q1	$1.29M	Buy	211,753 +139,449	+193%	+$1.03M	0.03%	513
2021 Q4	$662K	Buy	+72,304	New	+$768K	0.02%	808

Other funds holding ALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's ALT Position: Q2 2026 in Review

Walleye Capital increased its Altimmune (ALT) stake by 424,850% in Q2 2026, buying an estimated $25.4K and bringing the position to 8,499 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4343.

Walleye Capital first reported a position in ALT in Q4 2021 and has held it in 13 quarters since. The position peaked at $1.58M in Q2 2022. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

Walleye Capital held 8,499 shares of Altimmune worth $25.8K as of Q2 2026.
Walleye Capital bought 8,497 Altimmune shares in Q2 2026, an estimated $25.4K.
Altimmune made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4343 holding.
Walleye Capital first reported a position in Altimmune in Q4 2021 and has held it in 13 quarters since.
Walleye Capital's Altimmune position peaked at $1.58M in Q2 2022.
210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.